# Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

> **NCT01933061** · PHASE2 · WITHDRAWN · sponsor: **Celgene Corporation**

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT01933061
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic decision not to proceed with the opening of this study. There are no concerns over the safety or quality of the investigational products involved.
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933061, "Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01933061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*